Pre-operative hemostatic assessment and management

Transfusion and Apheresis Science

Volumn 27, Issue 1, 2002, Pages 45-53

  Baker, Ross ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOCAPROIC ACID; BLOOD CLOTTING FACTOR CONCENTRATE; CLOPIDOGREL; DESMOPRESSIN; FRESH FROZEN PLASMA; HEPARIN; IMMUNOGLOBULIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID; VITAMIN K GROUP; VON WILLEBRAND FACTOR; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING DISORDER; BLEEDING TENDENCY; CONSULTATION; DISEASE SEVERITY; DRUG HALF LIFE; FIBRINOLYSIS; FLUSHING; HEADACHE; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; HYPOTENSION; LABORATORY TEST; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PAIN; POSTOPERATIVE THROMBOSIS; PREDICTION; PREOPERATIVE PERIOD; REVIEW; RISK ASSESSMENT; SYMPTOM; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

EID: 0036083850     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(02)00025-3     Document Type: Article

References (39)

1. Clinical evaluation of hemorrhagic disorders: The bleeding history and differential diagnosis
2. Epidemiological investigation of the prevalence of von Willebrand disease
3. Genetics of classic von Willebrand's disease. II. Optimal assignment of the heterozygous genotype (diagnosis) by discriminant analysis
4. Applications of indicators, predictors and diagnostic indices in coagulation disorders. II. Evaluation of laboratory variables with continuous test results
5. Applications of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self administered questionnaire with binary questions
6. Approach to the bleeding patient
7. The bleeding time does not predict surgical bleeding
8. A prospective multicenter evaluation of preoperative hemostatic screening tests. The French Associations for Surgical Research
9. Impact, diagnosis and treatment of von Willebrand disease
10. Von Willebrand disease in a pediatric population-comparison of Type 1 diagnostic criteria and use of the PFA-100 and von Willebrand factor/collagen-binding assay
11. Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder
12. Getting at the variable expression of von Willebrand disease
13. The effect of ABO blood group on the diagnosis of von Willebrand disease
14. Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation
15. Genetic analysis of classic von Willebrand disease: I. Phenotypic variation within families
16. Serial studies in von Willebrand disease: Variable versus "variants"
17. Possible effect of secretor locus on plasma concentation of Factor VIII and von Willebrand factor
18. 1 levels in type 1 von Willebrand disease correlate with impaired platelet function in a high shear stress system
19. Moderation of hemophilia A phenotype by the factor V R506Q mutation
20. The hemophilias - From royal genes to gene therapy
21. Incidence of inhibitors in hemophilia A patients-review of recent studies of recombinant and plasma derived factor VIII concentrates
22. Inhibitors in hemophilia
23. Use of recombinant factor VIIa in hereditary bleeding disorders
24. Desmopressin (DDAVP) in the treatment of bleeding disorders. The first 20 years
25. Desmopressin: Therapeutic limitations in children and adults with inherited coagulation disorders
26. Treatment of von Willebrand disease
27. Treatment of von Willebrand disease with a high purity factor VIII/von Willebrand factor concentrate: A prospective multicenter study
28. Hematological problems in the surgical patient: Bleeding and thrombosis
29. Platelet function in myeloproliferative disorders: Characterisation and sequential studies show multiple platelet abnormalities, and change with time
30. Management of anticoagulation before and after elective surgery
31. Physician preferences for perioperative anticoagulation in patients with mechanical heart valve who are undergoing elective non cardiac surgery
32. Temporary discontinuation of oral anticoagulants: Role of low molecular weight heparin
33. Outpatient peri-operative and peri-procedure treatment with dalteparin for chronically anticoagualated patients at high risk for thromboembolic complications
34. Use of enoxaparin for the chronically anticoagulated patient before and after procedures
35. Heparin and low molecular weight heparin: Mechanism of action, pharmacokinetics, dosing, monitoring, efficacy and safety
36. Managing oral anticoagulant therapy
37. Treatment of warfarin-associated coagulopathy with oral vitamin K: A randomised controlled trial
38. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
39. Platelet-active drugs: The relationships among dose, effectiveness, and side effects